StockDuty ← Dashboard Oct 26, 2026 01:00 PM ET
SignalFDA/Bio

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial

Amgen's cancer drug combo cut death risk by 58% in a lung cancer trial.

What happened: Amgen's Imdelltra combined with AstraZeneca's Imfinzi cut death risk by 58% versus Imfinzi alone in a lung cancer trial. Key numbers: Median survival was 21.1 months with the combination versus 12.7 months for Imfinzi alone. Death risk reduction was 58%. Why it matters: The trial result points to a survival advantage for the combination over Imfinzi alone in lung cancer, a comparison the content presents as the basis for the 58% figure.
Amgen's Imdelltra combined with AstraZeneca's Imfinzi cut death risk by 58% versus Imfinzi alone in a lung cancer trial.
The trial result points to a survival advantage for the combination over Imfinzi alone in lung cancer, a comparison the content presents as the basis for the 58% figure.
Sources